DR. REDDY'S LABORATORIES LIMITED

🇱🇰Sri Lanka

Country: 🇱🇰Sri Lanka

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)

Phase 2

Completed

Conditions: Psoriasis

Interventions: Drug: PPC-06 400 mg BID
Drug: Placebo
Drug: PPC-06 400 mg QD
Drug: PPC-06 600 mg

First Posted Date: 2018-02-05

Last Posted Date: 2022-04-01

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 426

Registration Number: NCT03421197

Locations: 🇺🇸
Site 133, Fountain Valley, California, United States
🇺🇸
Site 182, Los Angeles, California, United States
🇺🇸
Site 145, Hialeah, Florida, United States

and more 71 locations

A Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release Capsules

Phase 2

Completed

Conditions: Rosacea

Interventions: Drug: DFD-29 Extended Release Capsules (40 mg)
Drug: DFD-29 Extended Release Capsules (20 mg)
Drug: Oraycea® (doxycycline) Capsules
Drug: Placebo Capsules

First Posted Date: 2017-11-14

Last Posted Date: 2021-03-01

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 205

Registration Number: NCT03340961

Locations: 🇩🇪
Site 04, Potsdam, Germany
🇩🇪
Site 13, Bad Bentheim, Germany
🇩🇪
Site 05, Buxtehude, Germany

and more 11 locations

A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris

Phase 2

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Tazorac Cream, 0.1%
Drug: DFD-03 Lotion, 0.1%
Drug: DFD-03 Vehicle Lotion 0%
Drug: Tazorac Vehicle Cream 0%

First Posted Date: 2017-11-14

Last Posted Date: 2020-08-17

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 155

Registration Number: NCT03341910

Locations: 🇺🇸
International Dermatology Inc., Miami, Florida, United States

A Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks

Phase 3

Completed

Conditions: Acne Vulgaris

Interventions: Drug: DFD-03 (0% tazarotene) Lotion (Placebo)
Drug: DFD-03 (0.1% tazarotene) Lotion

First Posted Date: 2017-09-25

Last Posted Date: 2021-03-01

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 547

Registration Number: NCT03292640

Locations: 🇺🇸
Center for Dermatology Clinical Research Inc., Fremont, California, United States

A Study of the Safety and Efficacy of DFD-03 for the Treatment of Acne Vulgaris

Phase 3

Completed

Conditions: Acne Vulgaris

Interventions: Other: Placebo Comparator
Drug: DFD-03

First Posted Date: 2017-09-21

Last Posted Date: 2021-03-01

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 550

Registration Number: NCT03290027

Locations: 🇺🇸
Dr. Seemal, Plano, Texas, United States

Study on the Pharmacokinetics (PK) of DFN-15 vs Comparator and Food-effect on DFN-15 PK in Healthy Adult Subjects

Phase 1

Completed

Conditions: Migraine

Interventions: Drug: DFN-15 (fasted)
Drug: DFN-15 (fed)
Drug: Comparator Celebrex® (fed)

First Posted Date: 2017-09-14

Last Posted Date: 2018-02-13

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 24

Registration Number: NCT03282838

Locations: 🇺🇸
Celerion, Lincoln, Nebraska, United States

Levofloxacin as an Empirical Therapy in Patients With Complicated Urinary Tract Infections

Phase 4

Conditions: Urinary Tract Infection

Interventions: Drug: Levofloxacin

First Posted Date: 2017-05-19

Last Posted Date: 2017-05-19

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 214

Registration Number: NCT03160807

Locations: 🇰🇿
Scientific Centre of Urology named after B.U Dzharbusynov 2, Basenov street,, Almaty, Kazakhstan

A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment Period

Phase 2

Completed

Conditions: Actinic Keratosis (AK)

Interventions: Drug: Low dose DFD07 once daily
Drug: High dose DFD07 once daily
Drug: High dose DFD07 twice daily
Drug: Placebo twice daily

First Posted Date: 2017-04-17

Last Posted Date: 2019-04-24

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 240

Registration Number: NCT03116698

Locations: 🇺🇸
Investigator Site 18, Santa Ana, California, United States
🇺🇸
Investigator Site 16, Boca Raton, Florida, United States
🇺🇸
Investigator Site 11, San Antonio, Texas, United States

and more 17 locations

Bioavailability of DFN-15 at 3 Different Doses vs. Comparator and to Determine Dose-proportionality of DFN-15 in Fasting Healthy Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: DFN-15 Dose 2
Drug: DFN-15 Dose 1
Drug: DFN-15 Dose 3
Drug: Active Comparator

First Posted Date: 2017-02-14

Last Posted Date: 2018-02-13

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 16

Registration Number: NCT03051685

Locations: 🇺🇸
Site 1, Fargo, North Dakota, United States

Efficacy and Saafety of Omez Iin Patients With H.Pylori Associated Diseases

Phase 4

Completed

Conditions: GERD

Interventions: Drug: OMEZ 40
Drug: OMEZ 80

First Posted Date: 2016-10-04

Last Posted Date: 2016-10-04

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 120

Registration Number: NCT02922699

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy